An observational study in Asthma, sponsored by Imperial College London. Completed at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Imperial College London · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies in Asthma by Imperial College London — 4 open to participants now, 4 under way, none of them phase 3. Asthma · Imperial College London.
Among the 46 studies in Asthma by Imperial College London, this one is the 16th largest by enrollment of the 17 observational ones that give a count, is one of 2 that started in 2023, is one of 17 observational ones, and was the 45th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →4 of the 46 studies in Asthma by Imperial College London are open now, in 1 country. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18–75
Imperial College London · Sites in United Kingdom
Ages 18–55 · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 5 days–16 yrs · Healthy volunteers
Imperial College London · Sites in United Kingdom
Ages 18+
By country, each count listing its studies:
Of the 416 Asthma studies recruiting now, 141 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 146 take children under 18; 105 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 159 across 1,254 observational studies indexed under Asthma.
Median enrollment 43 across the 29 interventional studies, 66 across the 17 observational. Of the 33 that completed or were terminated, 24 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
Imperial College London is the lead sponsor of 844 studies on the registry; 181 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 46 studies in Asthma by Imperial College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to investigate the role of IL-5 in suppressing anti-viral immune responses in bronchial epithelial cells (BECs) and in peripheral blood mononuclear cells (PBMCs) from 5 people with asthma.
IL-5 has been shown to be present in higher levels in those with asthma, more so during viral infection. The investigators know from existing evidence that having increased levels of interferon (IFN) reduces asthma exacerbations and viral load. The investigators suspect that IL-5 reduces the immune response during viral infection in bronchial epithelial cells (BECs) and peripheral blood mononuclear cells (PBMCs) by reducing levels of IFN. The aim is to investigate if increased IL-5 in stable eosinophilic asthma and asthma exacerbations suppresses anti-viral immunity in bronchial epithelial cells and in peripheral blood mononuclear cells directly via IL-5 receptor signalling, suppressing rhinovirus induction of IFNs. The investigators also will evaluate if anti-IL-5 therapies suppress IL-5 concentrations in stable and exacerbated asthma in vivo and whether suppression of IL-5 in vivo restores deficient anti-viral immunity in BECs and PBMCs, thereby protecting against asthma exacerbations.
Those with mild asthma on as required salbutamol only.
Must be eligible for the study 'Mechanisms of Adverse Effects of Long-Acting Beta-Agonists in Asthma' (MAELABA) (19SM5101).
IFNB1 Expression in PBMCs Following IL-5 Treatment and RV-A16 Infection (MOI 1)
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
Time frame: 8 hours post infection
IFNB1 Expression in Bronchial Epithelial Cells (BECs) Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
Time frame: 8 hours post infection
IFN-β Protein Production in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.
Time frame: 24 hours after RV-A16 infection
IFN-β Protein Production in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.
Time frame: 24 hours after RV-A16 infection
IL5RA Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.
Time frame: 8 hours after RV-A16 infection
IL5RA Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.
Time frame: 8 hours after RV-A16 infection
CSF2RB Expression in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.
Time frame: 8 hours after RV-A16 infection
CSF2RB Expression in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.
Time frame: 8 hours after RV-A16 infection
RV-A16 Viral RNA Levels in PBMCs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.
Time frame: 8 hours after RV-A16 infection
RV-A16 Viral RNA Levels in BECs Infected With RV-A16 (MOI 1) Following IL-5 Treatment
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.
Time frame: 8 hours after RV-A16 infection
Participants with asthma were recruited and enrolled to provide blood and bronchial epithelial cell samples for ex vivo studies investigating the effects of interleukin-5 (IL-5) on antiviral responses to rhinovirus A16 (RV-A16).
| Milestone | Asthma Participants |
|---|---|
| Started | 8 |
| Completed | 8 |
| Not completed | 0 |
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 1808 ± 3384 |
| IL-5 10 ng/mL | 1333 ± 2329 |
| IL-5 50 ng/mL | 1206 ± 2309 |
| IL-5 100 ng/mL | 1396 ± 2599 |
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFNB1 mRNA expression was measured by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 40.35 ± 46.69 |
| IL-5 10 ng/mL | 67.14 ± 115.1 |
| IL-5 50 ng/mL | 115.3 ± 215.5 |
| IL-5 100 ng/mL | 93.84 ± 117.2 |
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.
| pg/mL | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 271.5 ± 178.2 |
| IL-5 10 ng/mL | 332.6 ± 215.1 |
| IL-5 50 ng/mL | 313.1 ± 161.9 |
| IL-5 100 ng/mL | 352.9 ± 92.8 |
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IFN-β protein levels were measured in cell culture supernatants 24 hours after infection.
| pg/mL | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 4.71 ± 6.153 |
| IL-5 10 ng/mL | 1.501 ± 1.797 |
| IL-5 50 ng/mL | 5.813 ± 7.26 |
| IL-5 100 ng/mL | 2.811 ± 2.897 |
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 13.4 ± 20.77 |
| IL-5 10 ng/mL | 4.742 ± 11.62 |
| IL-5 50 ng/mL | 2.829 ± 6.929 |
| IL-5 100 ng/mL | 0 ± 0 |
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. IL5RA mRNA expression was measured by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 12.07 ± 12.77 |
| IL-5 10 ng/mL | 39.86 ± 47.91 |
| IL-5 50 ng/mL | 9.747 ± 14.47 |
| IL-5 100 ng/mL | 28.79 ± 62.04 |
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 484.6 ± 373.7 |
| IL-5 10 ng/mL | 217.2 ± 267.9 |
| IL-5 50 ng/mL | 683.5 ± 948.7 |
| IL-5 100 ng/mL | 124.4 ± 203.4 |
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. CSF2RB mRNA expression was measured by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 286.7 ± 486.8 |
| IL-5 10 ng/mL | 14.33 ± 31.94 |
| IL-5 50 ng/mL | 68.91 ± 147.4 |
| IL-5 100 ng/mL | 55.49 ± 99.87 |
Peripheral blood mononuclear cells (PBMCs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 2718153 ± 5783089 |
| IL-5 10 ng/mL | 1227172 ± 2389034 |
| IL-5 50 ng/mL | 1223239 ± 2564335 |
| IL-5 100 ng/mL | 1810980 ± 3577180 |
Bronchial epithelial cells (BECs) isolated from participants with asthma were pretreated ex vivo with IL-5 and infected with rhinovirus A16 (RV-A16) at MOI 1. RV-A16 viral RNA levels were quantified by quantitative PCR 8 hours after infection.
| copies/µL cDNA | Asthma Participants |
|---|---|
| IL-5 0 ng/mL | 6782114 ± 7302029 |
| IL-5 10 ng/mL | 8171611 ± 6618586 |
| IL-5 50 ng/mL | 5758877 ± 3566248 |
| IL-5 100 ng/mL | 8118634 ± 7264645 |
Collected over Adverse events were monitored during bronchoscopy and the immediate post-procedure recovery period, until participants had returned to their normal level of consciousness, had stable vital signs, and were able to swallow, in accordance with hospital guidelines. This usually took around 2 hours. Follow-up assessments were also conducted 1 week after bronchoscopy.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asthma Participants | 0/8 (0%) | 0/8 (0%) | 0/8 (0%) |
| Age, Continuous(years) | Asthma Participants |
|---|---|
| Mean | 30.25 ± 11.54 |
| Sex: Female, Male(Participants) | Asthma Participants |
|---|---|
| Female | 6 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Asthma Participants |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 4 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Fractional exhaled nitric oxide (FeNO)(ppb (parts per billion)) | Asthma Participants |
|---|---|
| Mean | 50.25 ± 35.81 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2023 to primary completion in Dec 2025, 27 months.
Results were first posted in Nov 2026, 10 months after primary completion.
Of 366 non-industry observational studies under Asthma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 97. This study's 27 months is below that.
Counting every sponsor, half of 456 studies reached it within 36 months; a quarter within 18 and three quarters within 82.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: primary completion Sep 2024 → Dec 2025 and completion Sep 2024 → Dec 2025.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.